{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T02:09:56Z","timestamp":1773713396719,"version":"3.50.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010659","name":"Erasmus University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024592","name":"CSC","doi-asserted-by":"publisher","award":["202008520048"],"award-info":[{"award-number":["202008520048"]}],"id":[{"id":"10.13039\/501100024592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mycetoma caused by Madurella mycetomatis (eumycetoma) is a neglected tropical disease that forms tumorous lesions in the subcutaneous tissue. The current standard treatment for eumycetoma consists of antifungal treatment combined with surgery, with limited success rates. Due to lack of investment, there are currently no large drug discovery programmes for mycetoma. Repurposing screening can therefore offer an effective and economical way to identify drugs that can be effective in eumycetoma treatment. Therefore, in this study we determined the in vitro activity and in vivo efficacy of 5631 compounds present in the Oncode Drug Repurposing library.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In total, 5631 drugs from the Oncode Drug Repurposing library were screened for in vitro activity against M. mycetomatis using a CLSI-based in vitro susceptibility assay and CellTiter-Glo as a viability dye. Compounds that inhibited the metabolic activity were tested for in vivo activity in M. mycetomatis-infected Galleria mellonella larvae.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-eight compounds out of the 5631 drugs were able to inhibit the metabolic activity of M. mycetomatis at 2\u2005\u00b5M. Seventeen of the 28 compounds were azoles and 2 were toxic to G. mellonella and therefore not screened further. Two from the remaining 9 compounds, bay117085 (log-rank, P\u200a=\u200a0.0494) and IMD-0354 (log-rank, P\u200a=\u200a0.0043), prolonged the survival of M. mycetomatis-infected larvae. Both compounds were designed as NF-\u03baB inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NF-\u03baB inhibitors bay117085 and IMD-0354 were able to prolong the survival of M. mycetomatis-infected larvae.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf369","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:57:13Z","timestamp":1757591833000},"page":"3320-3328","source":"Crossref","is-referenced-by-count":2,"title":["A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-\u03baB inhibitors active against eumycetoma"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-2239","authenticated-orcid":false,"given":"Jingyi","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bjorn R","family":"van Doodewaerd","sequence":"additional","affiliation":[{"name":"Department of Cell and Chemical Biology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Biersack","sequence":"additional","affiliation":[{"name":"Organic Chemistry Laboratory, University Bayreuth , Bayreuth ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Verbon","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul P","family":"Geurink","sequence":"additional","affiliation":[{"name":"Department of Cell and Chemical Biology, Leiden University Medical Center , Leiden ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8652-8783","authenticated-orcid":false,"given":"Wendy W J","family":"van de Sande","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"2025120206223877600_dkaf369-B1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1093\/mmy\/myx061","article-title":"Closing the mycetoma knowledge gap","volume":"56","author":"van de Sande","year":"2018","journal-title":"Med Mycol"},{"key":"2025120206223877600_dkaf369-B2","doi-asserted-by":"publisher","first-page":"e0003423","DOI":"10.1128\/cmr.00034-23","article-title":"An updated list of eumycetoma causative agents and their differences in grain formation and treatment response","volume":"37","author":"van de Sande","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"2025120206223877600_dkaf369-B3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.clindermatol.2011.06.027","article-title":"Actinomycetoma and advances in its treatment","volume":"30","author":"Welsh","year":"2012","journal-title":"Clin Dermatol"},{"key":"2025120206223877600_dkaf369-B4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.clindermatol.2011.09.009","article-title":"Eumycetoma","volume":"30","author":"Estrada","year":"2012","journal-title":"Clin Dermatol"},{"key":"2025120206223877600_dkaf369-B5","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/S1473-3099(24)00404-3","article-title":"Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial","volume":"24","author":"Fahal","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025120206223877600_dkaf369-B6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/myc.13442","article-title":"Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole","volume":"65","author":"Nyuykonge","year":"2022","journal-title":"Mycoses"},{"key":"2025120206223877600_dkaf369-B7","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/1346-8138.14607","article-title":"Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: a multicenter, double-blind, randomized phase III study","volume":"45","author":"Watanabe","year":"2018","journal-title":"J Dermatol"},{"key":"2025120206223877600_dkaf369-B8","doi-asserted-by":"publisher","first-page":"e0010159","DOI":"10.1371\/journal.pntd.0010159","article-title":"Screening the pandemic response box identified benzimidazole carbamates, olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma","volume":"16","author":"Lim","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2025120206223877600_dkaf369-B9","author":"MycetOS"},{"key":"2025120206223877600_dkaf369-B10","doi-asserted-by":"publisher","first-page":"e0006437","DOI":"10.1371\/journal.pntd.0006437","article-title":"Addressing the most neglected diseases through an open research model: the discovery of fenarimols as novel drug candidates for eumycetoma","volume":"12","author":"Lim","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2025120206223877600_dkaf369-B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ijms25116227","article-title":"Novel compound MMV1804559 from the global health priority box exhibits in vitro and in vivo activity against Madurella mycetomatis","volume":"26","author":"Ma","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025120206223877600_dkaf369-B12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/ijms26010315","article-title":"Repurposing FDA-approved drugs for eumycetoma treatment: homology modeling and computational screening of CYP51 inhibitors","volume":"26","author":"Mohamed","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2025120206223877600_dkaf369-B13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.4306","article-title":"The drug repurposing hub: a next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Nat Med"},{"key":"2025120206223877600_dkaf369-B14","author":"Oncode Institute"},{"key":"2025120206223877600_dkaf369-B15","author":"Oncode Institute"},{"key":"2025120206223877600_dkaf369-B16","doi-asserted-by":"publisher","first-page":"e0003926","DOI":"10.1371\/journal.pntd.0003926","article-title":"A Madurella mycetomatis grain model in Galleria mellonella larvae","volume":"9","author":"Kloezen","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2025120206223877600_dkaf369-B17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/myc.13561","article-title":"Comparing the performance of the common used eumycetoma diagnostic tests","volume":"66","author":"Siddig","year":"2023","journal-title":"Mycoses"},{"key":"2025120206223877600_dkaf369-B18","author":"Frische"},{"key":"2025120206223877600_dkaf369-B19","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/trstmh\/trae030","article-title":"The performance and costs of XTT, resazurin, MTS and luciferin as viability dyes in in vitro susceptibility testing of Madurella mycetomatis","volume":"118","author":"Ma","year":"2024","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2025120206223877600_dkaf369-B20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/mmy\/myx064","article-title":"Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis","volume":"56","author":"Kloezen","year":"2018","journal-title":"Med Mycol"},{"key":"2025120206223877600_dkaf369-B21","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/bjd.14025","article-title":"Amphotericin B but not itraconazole is able to prevent grain formation in experimental Madurella mycetomatis mycetoma in mice","volume":"173","author":"van de Sande","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025120206223877600_dkaf369-B22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/trstmh\/traa184","article-title":"In vitro susceptibility testing for black grain eumycetoma causative agents","volume":"115","author":"van de Sande","year":"2021","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2025120206223877600_dkaf369-B23","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1128\/AAC.01546-09","article-title":"Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents","volume":"54","author":"van de Sande","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223877600_dkaf369-B24","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1128\/AAC.49.4.1364-1368.2005","article-title":"Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method","volume":"49","author":"van de Sande","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223877600_dkaf369-B25","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/myc.13509","article-title":"Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma","volume":"65","author":"Nyuykonge","year":"2022","journal-title":"Mycoses"},{"key":"2025120206223877600_dkaf369-B26","doi-asserted-by":"publisher","first-page":"e0043321","DOI":"10.1128\/AAC.00433-21","article-title":"Comparison of disc diffusion, E-test and a modified CLSI broth microdilution method for in vitro susceptibility testing of itraconazole, posaconazole and voriconazole against Madurella mycetomatis","volume":"65","author":"Nyuykonge","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223877600_dkaf369-B27","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1128\/AAC.01170-12","article-title":"In vitro antifungal activity of isavuconazole to Madurella mycetomatis","volume":"56","author":"Kloezen","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206223877600_dkaf369-B28","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.micinf.2007.05.015","article-title":"Melanin biosynthesis in Madurella mycetomatis and its effect on susceptibility to itraconazole and ketoconazole","volume":"9","author":"van de Sande","year":"2007","journal-title":"Microbes Infect"},{"key":"2025120206223877600_dkaf369-B29","doi-asserted-by":"publisher","first-page":"e13664","DOI":"10.1111\/myc.13664","article-title":"Using (1,3)-\u03b2-D-glucan concentrations in serum to monitor the response of azole therapy in patients with eumycetoma caused by Madurella mycetomatis","volume":"67","author":"Nyuykonge","year":"2024","journal-title":"Mycoses"},{"key":"2025120206223877600_dkaf369-B30","doi-asserted-by":"publisher","first-page":"21096","DOI":"10.1074\/jbc.272.34.21096","article-title":"Novel inhibitors of cytokine-induced I\u03baB\u03b1 phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo","volume":"272","author":"Pierce","year":"1997","journal-title":"J Biol Chem"},{"key":"2025120206223877600_dkaf369-B31","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.7150\/ijbs.85158","article-title":"I\u03baB kinase \u03b2 (IKK\u03b2): structure, transduction mechanism, biological function, and discovery of its inhibitors","volume":"19","author":"Zhang","year":"2023","journal-title":"Int J Biol Sci"},{"key":"2025120206223877600_dkaf369-B32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10456-018-9594-9","article-title":"Selective IKK2 inhibitor IMD0354 disrupts NF-\u03baB signaling to suppress corneal inflammation and angiogenesis","volume":"21","author":"Lennikov","year":"2018","journal-title":"Angiogenesis"},{"key":"2025120206223877600_dkaf369-B33","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3389\/fphys.2018.01189","article-title":"The NF-\u03baB inhibitor, IMD-0354, affects immune gene expression, bacterial microbiota and Trypanosoma cruzi infection in Rhodnius prolixus midgut","volume":"9","author":"Vieira","year":"2018","journal-title":"Front Physiol"},{"key":"2025120206223877600_dkaf369-B34","doi-asserted-by":"publisher","first-page":"e1001750","DOI":"10.1371\/journal.pbio.1001750","article-title":"The velvet family of fungal regulators contains a DNA-binding domain structurally similar to NF-\u03baB","volume":"11","author":"Ahmed","year":"2013","journal-title":"PLoS Biol"},{"key":"2025120206223877600_dkaf369-B35","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3389\/fmicb.2015.01453","article-title":"Screening of pharmacologically active small molecule compounds identifies antifungal agents against Candida biofilms","volume":"6","author":"Watamoto","year":"2015","journal-title":"Front Microbiol"},{"key":"2025120206223877600_dkaf369-B36","doi-asserted-by":"publisher","first-page":"101381","DOI":"10.1016\/j.mycmed.2023.101381","article-title":"In vitro antifungal and antibiofilm activities of auranofin against itraconazole-resistant Aspergillus fumigatus","volume":"33","author":"Chen","year":"2023","journal-title":"J Mycol Med"},{"key":"2025120206223877600_dkaf369-B37","doi-asserted-by":"publisher","first-page":"1179354","DOI":"10.3389\/frabi.2023.1179354","article-title":"Gold complex compounds that inhibit drug-resistant Staphylococcus aureus by targeting thioredoxin reductase","volume":"2","author":"Tharmalingam","year":"2023","journal-title":"Front Antibiot"},{"key":"2025120206223877600_dkaf369-B38","doi-asserted-by":"publisher","first-page":"e86745","DOI":"10.1371\/journal.pone.0086745","article-title":"The role of IKK\u03b2 in Venezuelan equine encephalitis virus infection","volume":"9","author":"Amaya","year":"2014","journal-title":"PLoS One"},{"key":"2025120206223877600_dkaf369-B39","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/1348-0421.12828","article-title":"Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2","volume":"64","author":"Kato","year":"2020","journal-title":"Microbiol Immunol"},{"key":"2025120206223877600_dkaf369-B40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/antibiotics9100665","article-title":"New antimicrobial bioactivity against multidrug-resistant Gram-positive bacteria of kinase inhibitor IMD0354","volume":"9","author":"Escobar","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2025120206223877600_dkaf369-B41","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.3390\/ijms25115977","article-title":"The antifungal potential of niclosamide and structurally related salicylanilides","volume":"25","author":"Biersack","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025120206223877600_dkaf369-B42","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.3390\/molecules26134005","article-title":"Niclosamide is active in vitro against mycetoma pathogens","volume":"26","author":"Mahmoud","year":"2021","journal-title":"Molecules"},{"key":"2025120206223877600_dkaf369-B43","doi-asserted-by":"publisher","first-page":"8435","DOI":"10.4049\/jimmunol.179.12.8435","article-title":"Candida albicans triggers activation of distinct signaling pathways to establish a proinflammatory gene expression program in primary human endothelial cells","volume":"179","author":"Muller","year":"2007","journal-title":"J Immunol"},{"key":"2025120206223877600_dkaf369-B44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.imbio.2013.06.013","article-title":"Activation of NF-\u03baB and respiratory burst following Aspergillus fumigatus stimulation of macrophages","volume":"219","author":"Sun","year":"2014","journal-title":"Immunobiology"},{"key":"2025120206223877600_dkaf369-B45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11010-009-0211-5","article-title":"Role of phosphatidylinositol-3-kinase (PI3K), extracellular signal-regulated kinase (ERK) and nuclear transcription factor kappa \u03b2 (NF-k\u03b2) on neutrophil phagocytic process of Candida albicans","volume":"333","author":"Giraldo","year":"2010","journal-title":"Mol Cell Biochem"},{"key":"2025120206223877600_dkaf369-B46","author":"MycetOS"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3320\/64420834\/dkaf369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3320\/64420834\/dkaf369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:42Z","timestamp":1764674562000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3320\/8267121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,9,29]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf369","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,29]]}}}